On March 23, 2019, Amgen held a market meeting of Rybian (English name Repatha, commonly known as evolocumab iloyu monoclonal antibody) in Beijing.
This product was first approved in China in July 2018 for the treatment of homozygous familial hypercholesterolemia (HoFH) in adults or adolescents over 12 years old. In January 2019,
Rybian was approved for adult patients with atherosclerotic cardiovascular disease to reduce the risk of myocardial infarction, stroke and coronary revascularization.
It is estimated that the annual cost of this product is about 100,000 yuan, and the price of new drugs is not expensive, which can meet the needs of high-level payment patients.
Pharnex Datamonitor showed that domestic Kangfang Dongrui Joint Venture Company and Xinda entered Phase II clinical research.
